Cardiovascular Complications and Diabetes

The interplay between cardiovascular complications and diabetes presents a significant challenge in patient management. Chronic hyperglycemia, insulin resistance, and dyslipidemia contribute to atherosclerosis, increasing the risk of heart attacks and strokes. Emerging evidence supports the cardioprotective effects of GLP-1 receptor agonists and SGLT2 inhibitors, offering benefits beyond glucose control. Continuous monitoring of blood pressure, lipid profiles, and inflammatory markers is essential for early intervention. Lifestyle modifications, such as dietary adjustments and structured exercise programs, complement pharmacological strategies in reducing cardiovascular risk. Advances in precision cardiology and personalized treatments are paving the way for improved long-term outcomes in diabetic patients.

Committee Members
Speaker at Diabetes 2026 - Mahir Khalil Ibrahim Jallo

Mahir Khalil Ibrahim Jallo

Gulf Medical University, Canada
Speaker at Diabetes 2026 - F Buck Willis

F Buck Willis

Christian College of Medicine, Belize
Speaker at Diabetes 2026 - Anil Harrison

Anil Harrison

Midwestern University, United States
Speaker at Diabetes 2026 - Wan Rosli Wan Ishak

Wan Rosli Wan Ishak

Universiti Sains Malaysia, Malaysia
Diabetes 2026 Speakers
Speaker at Diabetes 2026 - Mahir Khalil Ibrahim Jallo

Mahir Khalil Ibrahim Jallo

Gulf Medical University, Canada
Speaker at Diabetes 2026 - F Buck Willis

F Buck Willis

Christian College of Medicine, Belize
Speaker at Diabetes 2026 - Anil Harrison

Anil Harrison

Midwestern University, United States
Speaker at Diabetes 2026 - David Navazio

David Navazio

Gentell, United States
Speaker at Diabetes 2026 - Sujith Rajan

Sujith Rajan

NYU Long Island School of Medicine, United States
Speaker at Diabetes 2026 - David Petch

David Petch

utR Biotech, Canada
Tags

Submit your abstract Today

YouTube
WhatsAppWhatsApp